Please login to the form below

Not currently logged in


This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.

After Axovant shock, Roivant pens diabetes deal with Poxel

After Axovant shock, Roivant pens diabetes deal with Poxel

After Axovant shock, Roivant pens diabetes deal with Poxel. Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal. ... It’s been a mixed few days for biotech entrepreneur Vivek Ramaswamy and his company Roivant Sciences, with a

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...